<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TIPRANAVIR</span><br/>(ti-pra'na-vir)<br/><span class="topboxtradename">Aptivus<br/></span><b>Classifications:</b> <span class="classification">antiretroviral agent</span>; <span class="classification">antiinfective agent</span>; <span class="classification">hiv protease inhibitor</span><br/><b>Prototype: </b>Saquinavir<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits virus-specific processing of the viral polyproteins in HIV-1 infected cells, thus preventing the formation of mature
         viral particles.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Helps decrease the viral load of the HIV-1 strains resistant to other protease inhibitors.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of HIV-1 infection in adults with evidence of viral replication who are highly treatment-experienced or have HIV-1
         strains resistant to multiple protease inhibitors. Tipranavir should be used in combination with ritonavir 200 mg and other
         antiretroviral agents.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to any of the ingredients in tipranavir; moderate to severe (Child-Pugh class B and C, respectively)
         hepatic insufficiency; pancreatitis; lactation. Safety and efficacy in children have not been established. 
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with chronic hepatitis B or hepatitis C coinfection; elevated liver enzymes; diabetic mellitus or hyperglycemia;
         hyperlipidemia; concurrent administration with HMG-CoA inhibitors; pregnancy (category C). 
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV-1 Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg (with 200 mg ritonavir) b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Coadminister with 200 mg ritonavir. Give with food.</li>
<li>Store at 15°30° C (59°86° F). Once opened, use contents of bottle within 60 d.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fatigue, pyrexia. <span class="typehead">CNS:</span> Asthenia, depression, headache, insomnia. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">diarrhea,</span> nausea, vomiting.  <span class="typehead">Hematological:</span> Decreased white blood cell levels. <span class="typehead">Hepatic:</span>
<span class="speceff-common">Elevated liver enzymes (amylase, ALT, AST).</span>
<span class="typehead">Metabolic:</span>
<span class="speceff-common">Increased cholesterol, increased triglycerides</span>. <span class="typehead">Respiratory:</span> Bronchitis, cough. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Aluminum</b> and <b>magnesium</b> based <span class="classification">antacids</span> may decrease tipranavir absorption. <span class="classification">azole antifungal agents</span>, <b>clarithromycin,</b>
<b>erythromycin,</b> and other inhibitors of CYP3A4 may increase tipranavir levels. <b>Efavirenz</b>, <b>loperamide</b>, <span class="classification">nrtis</span>, and <span class="classification">rifamycins</span> (e.g., <b>rifampin</b>) may decrease tipranavir levels. Tipranavir increases <b>rifabutin</b> levels. Coadministration of tipranavir and <b>tenofovir</b> decreases the levels of both compounds. Tipranavir increases the concentration of <span class="classification">benzodiazepines</span>, <b>desipramine,</b>
<span class="classification">ergot alkaloids</span>, and numerous <span class="classification">antiarrhythmic agents</span><b> (amiodarone, flecainide, propafenone, quinidine).</b> Tipranavir may decrease <b>ethinyl estradiol</b> levels by 50%. Combination use of tipranavir and <span class="classification">hmg coa reductase inhibitors</span> increases the risk of myopathy. Tipranavir capsules contain <b>alcohol</b> that can produce disulfiram-like reactions with <b>metronidazole</b> and <b>disulfiram.</b> <span class="typehead">Food:</span> Food enhances the bioavailability of tipranavir. <span class="typehead">Herbal:</span>
<b>St. John's wort</b> decreases the levels of tipranavir. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 3 h. <span class="typehead">Distribution:</span> &gt;99.9% protein bound. <span class="typehead">Metabolism:</span> Extensive hepatic oxidation to inactive metabolites (when given alone); minimal metabolism (when given with ritonavir). <span class="typehead">Elimination:</span> Fecal (primary) and renal (minimal). <span class="typehead">Half-Life:</span> 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report immediately S&amp;S of liver toxicity.</li>
<li>Monitor for S&amp;S of adverse drug reactions and toxicity from concurrently administered drugs. Many drugs interact with tipranavir.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Use barrier contraceptive if using hormonal contraceptive.</li>
<li>Lab tests: Baseline and frequent LFTs, especially in those with hepatitis B or C; periodic lipid profile and fasting plasma
            glucose.
         </li>
<li>Monitor blood levels of anticoagulants with concurrent therapy. </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Follow directions for taking the drug (see Administration). If a dose is missed, take it as soon as possible and then return
            to the normal schedule. Never double a dose.
         </li>
<li>Inform physician of all medications and herbal products you are taking.</li>
<li>Protect against sunlight exposure to minimize risk of photosensitivity.</li>
<li>Report any of the following to physician: fatigue, weakness, loss of appetite, nausea, jaundice, dark urine, or clay colored
            stools.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>